Company / Shareholders' Equity
Tyra Biosciences, Inc. Shareholders' Equity History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$343.2M
FY2024
5-year range
-$13.6M / $343.2M
FY2020-FY2024
Trend
+68.0%
vs FY2023
Sector context
#122 of 213
Health Care
What the data says
At $343M, Tyra Biosciences, Inc.'s shareholders' equity ranks #122 of 213 in the Health Care sector. Shareholders' Equity returned to growth in FY2024 after 2 years of decline, reaching $343M.
Based on SEC 10-K filings.
$343M in FY2024 with a 3-year CAGR of +4.4%.
Improved from $258M to $343M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +4.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#122 of 213 in Health CareTop 57% of 213This company $343.2M Sector average $2.5B
▼
-86.5% below sector average
Key checks
Key Insights
- 3-year CAGR of +4.4%, indicating consistent growth.
- In FY2024, shareholders' equity increased 68.0% year-over-year.
- Ranks #122 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 6.83 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $343.2M | +68.0% |
| FY2023 | $204.3M | -20.8% |
| FY2022 | $257.8M | -14.6% |
| FY2021 | $301.7M | +2312.5% |
| FY2020 | -$13.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026